References
- Korman NJ, Zhao Y, Pike J, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol 2016;41:514-21
- Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One 2012;7:e52935
- Takeshita J, Callis Duffin K, Shin DB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol 2014;71:633-41
- Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatolog Treat 2015;26:235-9
- Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis J Am Acad Dermatol 2016;75:77-82.e7
- Rabin R, deCharro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43
- Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345-56
- Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386:541-51
- Gordon K, Blauvelt A, Langley R, et al. Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1) [abstract]. Late-Breaking Research Abstract Forums: American Academy of Dermatology Annual Meeting; 2015, San Francisco, CA, March 20–24; Abstract Book, p 19
- Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014;371:326-38
- Kalb RE, Blauvelt A, Sofen HL, et al. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol 2013;12:874-80.
- Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158:549-57
- Norlin JM, Steen Carlsson K, Persson U, et al. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology 2012;225:326-32
- Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 2016;9:39-50
- Norlin JM, Steen Carlsson K, Persson U, et al. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol 2012;166:797-802
- Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(2 Suppl):ii65-8
- Wade R, Hinde S, Yang H, et al. Apremilast for treating moderate to severe plaque psoriasis: a single technology appraisal. Heslington, York (England): CRD and CHE Technology Group, 2015. http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0011/159977/ERGReport-13-168-01.pdf. Accessed July 21, 2016
- National Institute for Health and Clinical Excellence. Ustekinumab (Stelara™) for the treatment of moderate to severe plaque psoriasis in England & Wales. London (England): Janssen-Cilag Ltd, 2009. https://www.nice.org.uk/guidance/ta180/documents/psoriasis-ustekinumab-manufacturer-submission-janssencilag2. Accessed July 21 2016
- Cummins E, Scott N, Cruickshank M, et al. Secukinumab for treating moderate to severe plaque psoriasis: a single technology appraisal. Aberdeen, UK: Aberdeen HTA Group, 2015. http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0005/146426/ERGReport-13-129-01.pdf. Accessed July 21 2016
- National Institute for Health and Care Excellence. Adalimumab for the treatment of adults with psoriasis. NICE technology appraisal. London (England): Abbott Laboratories, Ltd, 2008. https://www.nice.org.uk/guidance/TA146/documents/psoriasis-adalimumab-appraisal-consultation-manufacturer-submission-abbott-laboratories-ltd2. Accessed July 21, 2016
- Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6
- Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36
- Van Reenen M, Janssen B. EQ-5D-5L User guide: basic information on how to use the EQ-5D-5L instrument. Rotterdam (Netherlands): EuroQol Group, 2015
- EuroQol [Internet]. How to obtain EQ-5D. Rotterdam, Netherlands: EUROQOL, c2016. http://www.euroqol.org/eq-5d-products/how-to-obtain-eq-5d.html. Accessed May 19, 2016
- Swinburn P, Lloyd A, Boye KS, et al. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health 2013;16:1156-62
- Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
- Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20
- Devlin N, Shah K, Feng Y, et al. Valuing health-related quality of life: an EQ-5D-5L value set for England. London, UK: University of Sheffield, 2015, https://www.shef.ac.uk/polopoly_fs/1.546914!/file/An_EQ-5D-5L_Value_Set_for_England_DP_Final.pdf. Accessed August 4, 2016
- van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15
- Guh D, Papp K, Lynde C, et al. Impact of adalimumab on quality of life and depression in psoriasis patients: Results from PRIDE [abstract]. Value Health 2010;13:A148
- Reich K, Segaert S, van de Kerkhof P, et al. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. Dermatology 2009;219:239-49
- Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007;18:25-31
- Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24(2 Suppl):17-22
- Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ 2015;16:927-39